BRPI0415896A - combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia - Google Patents

combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia

Info

Publication number
BRPI0415896A
BRPI0415896A BRPI0415896-2A BRPI0415896A BRPI0415896A BR PI0415896 A BRPI0415896 A BR PI0415896A BR PI0415896 A BRPI0415896 A BR PI0415896A BR PI0415896 A BRPI0415896 A BR PI0415896A
Authority
BR
Brazil
Prior art keywords
inhibitor
treating
combinations
preventing cancer
phosphodiesterase
Prior art date
Application number
BRPI0415896-2A
Other languages
English (en)
Inventor
Jaime L Masferrer
Thomas D Penning
Xing Wang
Deborah M Heuvelman
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BRPI0415896A publication Critical patent/BRPI0415896A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"COMBINAçõES COMPREENDENDO UM INIBIDOR DE Hsp90 E UM INIBIDOR DE FOSFODIESTERASE PARA TRATAMENTO OU PREVENçãO DE NEOPLASIA". é providenciado um método para tratar ou prevenir neoplasia, ou um distúrbio relacionado com neoplasia num indivíduo, compreendendo o método a administração ao indivíduo de uma quantidade eficaz de uma combinação, compreendendo um inibidor de Hsp90 e um inibidor de fosfodiesterase, e, opcionalmente um inibidor de Cox-2.
BRPI0415896-2A 2003-10-28 2004-10-28 combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia BRPI0415896A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51502103P 2003-10-28 2003-10-28
PCT/US2004/035949 WO2005041879A2 (en) 2003-10-28 2004-10-28 COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA

Publications (1)

Publication Number Publication Date
BRPI0415896A true BRPI0415896A (pt) 2007-01-09

Family

ID=34549367

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415896-2A BRPI0415896A (pt) 2003-10-28 2004-10-28 combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia

Country Status (6)

Country Link
EP (1) EP1682143A2 (pt)
JP (1) JP2007509968A (pt)
BR (1) BRPI0415896A (pt)
CA (1) CA2543503A1 (pt)
MX (1) MXPA06004657A (pt)
WO (1) WO2005041879A2 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS52642B (en) 2004-11-18 2013-06-28 Synta Pharmaceuticals Corp. TRIAZOLE COMPOUNDS MODULATING HSP90 ACTIVITY
US8399464B2 (en) 2005-03-09 2013-03-19 Nippon Kayaku Kabushiki Kaisha HSP90 inhibitor
AU2006224623A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
CA2700893A1 (en) * 2007-10-12 2009-04-16 Arqule, Inc. Substituted tetrazole compounds and uses thereof
WO2009140621A2 (en) * 2008-05-15 2009-11-19 Duke University Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2384752A1 (de) * 2010-04-14 2011-11-09 Universitätsklinikum Hamburg-Eppendorf Kombinationspräparat umfassend einen Phosphodiesterasehemmer und einen COX-Inhibitor zur Behandlung von Krebs
WO2011133520A1 (en) 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
EP2773345A1 (en) 2011-11-02 2014-09-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
CN103102306A (zh) * 2013-02-06 2013-05-15 河南东泰制药有限公司 一种塞来昔布的制备方法
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
TW201506024A (zh) 2013-07-02 2015-02-16 必治妥美雅史谷比公司 作為有效ｒｏｃｋ抑制劑的三環甲醯胺衍生物
CN104069113B (zh) * 2014-07-08 2016-08-31 山东大学齐鲁医院 西地那非在制备治疗抗血管瘤的药物中的应用
TW202039504A (zh) * 2018-12-31 2020-11-01 美商拜歐米富士恩有限公司 Ｍｅｎｉｎ-ｍｌｌ相互作用之不可逆抑制劑
CA3125353A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
CN112679470B (zh) * 2021-01-06 2023-01-13 中国药科大学 (e)-1-苯基4-烯基-1h-吡唑类化合物及其医药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
CA2447066A1 (en) * 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US20030157061A1 (en) * 2001-12-05 2003-08-21 Pharmacia Corporation Combinations of a cyclooxygenase-2 selective inhibitor and a TNFalpha antagonist and therapeutic uses therefor

Also Published As

Publication number Publication date
WO2005041879A3 (en) 2005-10-06
MXPA06004657A (es) 2006-06-27
CA2543503A1 (en) 2005-05-12
WO2005041879A2 (en) 2005-05-12
EP1682143A2 (en) 2006-07-26
JP2007509968A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
BRPI0415896A (pt) combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia
WO2005044194A3 (en) TREATMENT OR PREVENTION OF NEOPLASIA BY USE OF AN Hsp90 INHIBITOR
CR8181A (es) Uso de una combinacion de un inhibidor de la cinasa del receptor del factor de crecimiento epidermico y agentes citotoxicos para el tratamiento e inhibicion del cancer
BR0013219A (pt) Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
NZ544472A (en) Compounds and therapeutical use thereof
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
HUP0104688A2 (hu) Összetételek és eljárások a rákbetegség és a rákbetegséggel kapcsolódó csontveszteség megelőzéséhez és kezeléséhez
IL174965A0 (en) SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF Raf KINASE
EP1638514A4 (en) USE OF EPHA4 AND MODULATOR OR EPHA4 FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF CANCER
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
WO2005037323A3 (en) Use of gro to treat or prevent inflammation
ATE208763T1 (de) Trisubstituierte phenyl derivate
AR043660A1 (es) El tratamiento de la enfermedad de alzheimer
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
BRPI0409473A (pt) combinação de um inibidor de cox-2 e um agente antineoplásico do tipo alquilante para o tratamento de neoplasia
MXPA03006776A (es) Uso de inhibidores de interleucina-18 para el tratamiento y/o prevencion de enfermedad cardiaca.
BR0317947A (pt) Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes
BRPI0408500A (pt) tratamento do diabetes do tipo 1 com inibidores de pde5
BR0307085A (pt) Terapia combinada para o tratamento de infecções bacterianas
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
MXPA02012911A (es) Compuestos de rutenio (ii) para el uso en terapia del cancer.
PL357179A1 (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired